Hi Pat,
Thanks for the post. I just wanted to clarify something you mentioned. While I didn't attend the Investor Briefing, it is my understanding that Alan said the company needed another $50 million bewteen now and achieving cash-flow positive, NOT between now and commencing RTFS production, which is on schedule for March. This is a big difference. The company will now have $35 million of this amount following the CR/SPP, and will also have the ability to finance further capital equipment requirement, should they need to do so.
The prospect of up-front licence/exclusivity fees from additional pharma signing on for RTFS is shaping up as being the ace(s?) in the pack, and as such, tantalising to say the least.
So, all-in-all, as Booster, yourself and others have confirmed with your reports, we are in terrific shape to achieve what will prove to be a watershed year for Unilife in 2011.
All the best.
- Forums
- ASX - By Stock
- UNS
- ramblings of a mad ramper
ramblings of a mad ramper, page-23
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online